Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allergan Alphagan P

Executive Summary

Brimonidine ophthalmic solution .15%, approved March 16, will be launched by fall for lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Alphagan P, preserved with Purite, has comparable efficacy to Alphagan .2%, while reducing the risk of side effects

You may also be interested in...



Bausch & Lomb generic Alphagan

Bausch & Lomb receives approval May 28 for generic version of Allergan's Alphagan (brimonidine ophthalmic solution .2%); marketing exclusivity will run until Sept. 20. Allergan withdrew distribution of Alphagan .2% in August 2002 following launch of Alphagan P .15%, preserved with Purite, in 2001 (1"The Pink Sheet" March 26, 2001, In Brief). Allergan claims the .15% concentration is safer. However the firm's generic division, Pacific Pharma, plans to sell a generic version of the .2% formulation...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel